Tommy B. Andersson
About
Tommy B. Andersson is a scholar working on Pharmacology, Oncology and Molecular Biology.
According to data from OpenAlex, Tommy B. Andersson has authored 119 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Pharmacology, 58 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in Tommy B. Andersson's work include Pharmacogenetics and Drug Metabolism (79 papers), Drug Transport and Resistance Mechanisms (55 papers) and Drug-Induced Hepatotoxicity and Protection (24 papers). Tommy B. Andersson is often cited by papers focused on Pharmacogenetics and Drug Metabolism (79 papers), Drug Transport and Resistance Mechanisms (55 papers) and Drug-Induced Hepatotoxicity and Protection (24 papers). Tommy B. Andersson collaborates with scholars based in Sweden, United Kingdom and United States. Tommy B. Andersson's co-authors include Kajsa P. Kanebratt, Xueqing Li, Magnus Ingelman‐Sundberg, Collen Masimirembwa, Lars Weidolf, Marianne Ridderström, Inger Johansson, Charlotta Otter, Volker M. Lauschke and Catherine C. Bell and has published in prestigious journals such as Journal of Biological Chemistry, Hepatology and Scientific Reports.
In The Last Decade
Tommy B. Andersson
117 papers receiving 6.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tommy B. Andersson Sweden | 48 | 3.1k | 1.9k | 1.8k | 1.1k | 1.0k | 119 | 7.1k | ||
| Edward L. LeCluyse United States | 58 | 4.5k 1.5× | 3.2k 1.7× | 3.0k 1.7× | 1.3k 1.2× | 2.0k 1.9× | 135 | 11.3k | ||
| André Guillouzo France | 56 | 3.3k 1.1× | 2.6k 1.4× | 3.4k 1.9× | 1.4k 1.3× | 2.4k 2.4× | 192 | 10.0k | ||
| Jürgen Borlak Germany | 49 | 1.6k 0.5× | 1.0k 0.5× | 3.8k 2.1× | 729 0.7× | 624 0.6× | 201 | 8.7k | ||
| M. Teresa Donato Spain | 46 | 2.8k 0.9× | 1.5k 0.8× | 2.3k 1.3× | 1.1k 1.0× | 1.7k 1.7× | 143 | 7.4k | ||
| Noriaki Shimada Japan | 57 | 2.4k 0.8× | 1.4k 0.8× | 1.8k 1.0× | 450 0.4× | 252 0.2× | 207 | 9.6k | ||
| Ramiro Jover Spain | 43 | 1.8k 0.6× | 1.2k 0.6× | 1.9k 1.1× | 679 0.6× | 796 0.8× | 116 | 5.4k | ||
| M. José Gómez‐Lechón Spain | 38 | 1.8k 0.6× | 991 0.5× | 1.2k 0.7× | 671 0.6× | 874 0.9× | 82 | 4.4k | ||
| Bernard Fromenty France | 60 | 2.9k 0.9× | 1.0k 0.5× | 3.8k 2.1× | 860 0.8× | 2.0k 1.9× | 154 | 11.8k | ||
| Ute Hofmann Germany | 45 | 1.6k 0.5× | 1.9k 1.0× | 1.7k 0.9× | 743 0.7× | 261 0.3× | 183 | 6.3k | ||
| Andrew Parkinson United States | 44 | 3.3k 1.1× | 1.8k 0.9× | 1.7k 1.0× | 314 0.3× | 391 0.4× | 120 | 6.4k |
Countries citing papers authored by Tommy B. Andersson
Since
Specialization
Citations
This map shows the geographic impact of Tommy B. Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tommy B. Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tommy B. Andersson more than expected).
Fields of papers citing papers by Tommy B. Andersson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tommy B. Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tommy B. Andersson. The network helps show where Tommy B. Andersson may publish in the future.
Co-authorship network of co-authors of Tommy B. Andersson
This figure shows the co-authorship network connecting the top 25 collaborators of Tommy B. Andersson. A scholar is included among the top collaborators of Tommy B. Andersson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tommy B. Andersson. Tommy B. Andersson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vildhede, Anna, Tommy B. Andersson, Fredrik Erlandsson, et al.. (2021). In Vitro Assessment of the Drug–Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters. Journal of Pharmacology and Experimental Therapeutics. 378(2). 108–123.
2.
Robertsen, Ida, Marianne Kristiansen Kringen, Maria Vistnes, et al.. (2020). Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes. Journal of Pharmaceutical Sciences. 110(1). 432–437.
3.
Wegler, Christine, Fabienne Z. Gaugaz, Tommy B. Andersson, et al.. (2016). Protein quantification of human hepatic drug transporters and metabolizing enzymes: an inter-laboratory and methodological comparison. Drug Metabolism Reviews. 48. 98–98.
4.
Olsson, Björn, Josefina Edsbagge, Barbara Küppers-Munther, et al.. (2016). Highly Synchronized Expression of Lineage‐Specific Genes during In Vitro Hepatic Differentiation of Human Pluripotent Stem Cell Lines. Stem Cells International. 2016(1). 8648356–8648356.
5.
Holmgren, Gustav, Anna-Karin Sjögren, Isabel Barragán, et al.. (2014). Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cell–Derived Hepatocytes. Drug Metabolism and Disposition. 42(9). 1401–1406.
6.
Nordell, Pär, Annika Asplund, Gustav Holmgren, et al.. (2013). Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochemical Pharmacology. 86(5). 691–702.
7.
Schreiter, Thomas, G. Marquitan, Malin Darnell, et al.. (2012). An Ex Vivo Perfusion System Emulating In Vivo Conditions in Noncirrhotic and Cirrhotic Human Liver. Journal of Pharmacology and Experimental Therapeutics. 342(3). 730–741.
8.
Jakobsen, Gunn Signe, Sara Bremer, Espen Molden, et al.. (2012). Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects. Clinical Pharmacology & Therapeutics. 93(3). 275–282.
9.
Zeilinger, Katrin, Thomas Schreiter, Malin Darnell, et al.. (2011). Scaling Down of a Clinical Three-Dimensional Perfusion Multicompartment Hollow Fiber Liver Bioreactor Developed for Extracorporeal Liver Support to an Analytical Scale Device Useful for Hepatic Pharmacological In Vitro Studies. Tissue Engineering Part C Methods. 17(5). 549–556.
10.
Sjögren, Erik, Ulf Bredberg, Björn Arvidsson, et al.. (2010). Hepatic Disposition of Ximelagatran and Its Metabolites in Pig; Prediction of the Impact of Membrane Transporters Through a Simple Disposition Model. Pharmaceutical Research. 27(4). 597–607.
11.
Diczfalusy, Ulf, Kajsa P. Kanebratt, Eva Bredberg, et al.. (2008). 4β‐Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half‐life of elimination after induction with rifampicin. British Journal of Clinical Pharmacology. 67(1). 38–43.
12.
Kanebratt, Kajsa P. & Tommy B. Andersson. (2007). HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans. Drug Metabolism and Disposition. 36(1). 137–145.
13.
Kenne, Kerstin, Inger Skånberg, Björn Glinghammar, et al.. (2007). Prediction of drug-induced liver injury in humans by using in vitro methods: The case of ximelagatran. Toxicology in Vitro. 22(3). 730–746.
14.
Hofmann, Yvonne, Åsa Nordling, Xueqing Li, et al.. (2005). CHARACTERIZATION AND PARTIAL PURIFICATION OF THE RAT AND HUMAN ENZYME SYSTEMS ACTIVE IN THE REDUCTION OF N-HYDROXYMELAGATRAN AND BENZAMIDOXIME. Drug Metabolism and Disposition. 33(4). 570–578.
15.
Li, Xueqing, et al.. (2004). COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES. Drug Metabolism and Disposition. 32(8). 821–827.
16.
Andersson, Tommy B., et al.. (2004). AN EVALUATION OF THE IN VITRO METABOLISM DATA FOR PREDICTING THE CLEARANCE AND DRUG-DRUG INTERACTION POTENTIAL OF CYP2C9 SUBSTRATES. Drug Metabolism and Disposition. 32(7). 715–721.
17.
Bredberg, Eva, Tommy B. Andersson, Lars Frison, et al.. (2003). Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions. Clinical Pharmacokinetics. 42(8). 765–777.
18.
Bapiro, Tashinga E., Tommy B. Andersson, Charlotta Otter, Julia A. Hasler, & Collen Masimirembwa. (2002). Cytochrome P 450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. European Journal of Clinical Pharmacology. 58(8). 537–542.
19.
Löfberg, Lena, et al.. (1999). Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory Region. Biochemical and Biophysical Research Communications. 259(1). 201–205.
20.
Sadar, Marianne D., et al.. (1996). Phenobarbital Induction of Gene Expression in a Primary Culture of Rainbow Trout Hepatocytes. Journal of Biological Chemistry. 271(30). 17635–17643.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Edward L. LeCluyse Breakdown of academic impact, for papers by André Guillouzo Breakdown of academic impact, for papers by Jürgen Borlak Breakdown of academic impact, for papers by M. Teresa Donato Breakdown of academic impact, for papers by Noriaki Shimada Breakdown of academic impact, for papers by Ramiro Jover Breakdown of academic impact, for papers by M. José Gómez‐Lechón Breakdown of academic impact, for papers by Bernard Fromenty Breakdown of academic impact, for papers by Ute Hofmann Breakdown of academic impact, for papers by Andrew Parkinson